Lacosamide Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IA/0022 
A.5.b - Administrative change - Change in the name 
19/07/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
B.II.b.3.a - Change in the manufacturing process of 
19/07/2023 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0021/G 
This was an application for a group of variations. 
10/07/2023 
04/08/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019 
B.III.1.a.2 - Submission of a new/updated or 
08/03/2023 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0018 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/11/2022 
04/08/2023 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0017 
B.II.e.2.a - Change in the specification parameters 
30/09/2022 
n/a 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
R/0015 
Renewal of the marketing authorisation. 
23/06/2022 
24/08/2022 
SmPC, Annex 
II, Labelling 
and PL 
IA/0016 
A.7 - Administrative change - Deletion of 
10/01/2022 
24/08/2022 
Annex II and 
manufacturing sites 
PL 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/12/2021 
24/08/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
X/0007 
Annex I_2.(c) Change or addition of a new 
16/09/2021 
22/11/2021 
SmPC, Annex 
strength/potency 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
Annex I_2.(e) Change or addition of a new route of 
administration 
II, Labelling 
and PL 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/07/2021 
22/11/2021 
SmPC and PL 
To extend the indication to include the treatment as 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
adjective therapy of primary generalised tonic-clonic 
seizures in adults, adolscents and children from 4 years of 
age with idiopathic generalised epilepsy for lacosamide 
following assessment of the same change for the reference 
product 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0012 
B.III.1.a.3 - Submission of a new/updated or 
08/06/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0011 
B.II.b.3.z - Change in the manufacturing process of 
05/05/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0010 
B.III.1.a.1 - Submission of a new/updated or 
12/11/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IAIN/0008 
B.II.b.2.c.1 - Change to importer, batch release 
05/06/2020 
12/11/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0006/G 
This was an application for a group of variations. 
10/10/2019 
04/02/2020 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IA/0005 
B.II.b.2.a - Change to importer, batch release 
05/03/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0004/G 
This was an application for a group of variations. 
05/03/2019 
04/02/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
T/0002 
Transfer of Marketing Authorisation 
18/01/2019 
01/03/2019 
SmPC, 
Labelling and 
PL 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003/G 
This was an application for a group of variations. 
31/01/2019 
04/02/2020 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/02/2018 
04/04/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
